Travere Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Travere Therapeutics Inc.
Former names: Retrophin, Inc. Desert Gateway, Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: California
Headquarters city: SAN Diego
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: TVTX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001438533
EIN: 26-2383102

Board of directors

Follow this board

Brinkley Ruth Williams · Director
Since 2023
Eric M. Dube · Director · CHIEF EXECUTIVE OFFICER
Since 2023
Gary A. Lyons · Director
Since 2023
Jeffrey A. Meckler · Director
Since 2023
John A. Orwin · Director
Since 2023
Ron Squarer · Director
Since 2023
Roy D. Baynes · Director
Since 2023
Sandra Poole · Director
Since 2023
Suzanne Louise Bruhn · Director
Since 2023
Timothy Coughlin · Director Overboarded
Since 2023

Chief executives

Eric M. Dube · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of May 19, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

9 of this board's directors also sit on 16 other boards. 16 are in the same sector.

Shared director Other board Same sector

ADC Therapeutics SA Same sector
via Ron Squarer and Timothy Coughlin
Natera Inc. Same sector
via Brinkley Ruth Williams and Roy D. Baynes
Aardvark Therapeutics Inc. Same sector
via Roy D. Baynes
AnaptysBio Inc. Same sector
via John A. Orwin
Definium Therapeutics Inc. Same sector
via Suzanne Louise Bruhn
Eledon Pharmaceuticals Inc. Same sector
via Gary A. Lyons
Fate Therapeutics Inc. Same sector
via Timothy Coughlin
First Tracks Biotherapeutics Inc. Same sector
via John A. Orwin
Indaptus Therapeutics Inc. Same sector
via Jeffrey A. Meckler
Neurocrine Biosciences Inc. Same sector
via Gary A. Lyons
Nurix Therapeutics Inc. Same sector
via Roy D. Baynes
OnKure Therapeutics Inc. Same sector
via Eric M. Dube
Pliant Therapeutics Inc. Same sector
via Suzanne Louise Bruhn
Rigel Pharmaceuticals Inc. Same sector
via Gary A. Lyons
Vir Biotechnology Inc. Same sector
via Timothy Coughlin
aTyr Pharma Inc. Same sector
via Timothy Coughlin

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $110,398,272; 118 sales by 11 insiders

Date	Insider	Transaction	Shares	Price	Value
Oct 15, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+43,735	$26.88	$1,175,597
Oct 15, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+200,000	$8.93	$1,786,000
Oct 15, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−128,065	$52.97	$6,783,244
Oct 15, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−37,270	$54.20	$2,020,023
Oct 15, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−78,400	$55.02	$4,313,403
Sep 17, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+108,493	$23.34	$2,532,227
Sep 17, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−101,691	$64.59	$6,568,222
Sep 17, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−6,802	$64.95	$441,790
Sep 17, 2026	Heerma Peter Officer (EVP, CHIEF COMMERCIAL OFFICER)	Option exercise	+8,282	$22.40	$185,517
Sep 17, 2026	Heerma Peter Officer (EVP, CHIEF COMMERCIAL OFFICER)	Open-market sale	−8,282	$65.07	$538,910
Sep 16, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+195,841	$23.34	$4,570,929
Sep 16, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−99,716	$63.26	$6,308,034
Sep 16, 2026	ROTE WILLIAM E. Officer (Chief Research Officer)	Option exercise	+350	$17.96	$6,286
Sep 16, 2026	Eric M. Dube Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−96,125	$63.64	$6,117,395
Sep 16, 2026	Heerma Peter Officer (EVP, CHIEF COMMERCIAL OFFICER)	Option exercise	+100,000	$11.25	$1,125,000

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Travere Therapeutics Inc.

Who is the CEO of Travere Therapeutics Inc.?

Eric M. Dube is Travere Therapeutics Inc.'s Chief Executive Officer.

How many directors are on Travere Therapeutics Inc.'s board?

Travere Therapeutics Inc.'s board has 10 directors: Brinkley Ruth Williams, Eric M. Dube, Gary A. Lyons, Jeffrey A. Meckler, John A. Orwin, Ron Squarer, Roy D. Baynes, Sandra Poole, Suzanne Louise Bruhn and Timothy Coughlin.

Are Travere Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Travere Therapeutics Inc. insiders made no open-market purchases and sold $110.4 million of shares in 118 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Travere Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="travere-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.